Medpredict, Feb 2010, Pages: 146
amongst the most important mechanisms in development for ovarian cancer. Executive Summary
Top-Ten Report Highlights
- Key Findings
- Ovarian Cancer Standards of Care / Unmet Needs
- Subtypes
Espicom Business Intelligence Ltd, May 2010, Pages: 268
clinical trials. The majority of agents progressing through development are HSP90 inhibitors, with one HSP-based anticancer vaccine.
As a chaperone protein, HSP90 plays an important role in regulating
Datamonitor, Nov 2011, Pages: 166
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Sutent (sunitinib; Pfizer)
Drug profile
Development overview
SWOT analysis
John Wiley and Sons Ltd, Nov 2009, Pages: 526
on pharmacogenomics and its application to kinase inhibitor clinical development PREFACE.
CONTRIBUTORS.
PART I GROWTH FACTOR INHIBITORS: VEGFR2, ERBB2, AND OTHER KINASE.
1 Discovery and Development of Sunitinib
Decision Resources, Inc., June 2009, Pages: 31
Considerations
Stakeholder Implications
Introduction
Regulatory Structure
Ministry of Health
State Food and Drug Administration
Ministry of Human Resources and Social Security
National Development
Datamonitor, Oct 2011, Pages: 100
blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.
Features and benefits
- Sales forecasts
Decision Resources, Inc., Oct 2006, Pages: 30
Companion diagnostics will play an increasing role in cancer care. Pharmaceutical companies developing targeted therapies for cancer must consider the potential benefi ts of developing a companion
GlobalData, June 2011, Pages: 82
disease markets in the long run.
Reasons to buy
The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies
Informa Healthcare, Jan 2007
levels of the industry and recent developments.
Scrip Yearbook 2008 will help you to:
- Identify which significant mergers and acquisitions were completed
- Analyse the strategic and financial
Business Insights, Aug 2008, Pages: 121
Developing, manufacturing and marketing innovative new pharmaceutical drugs is highly complex and involves significant investment. Market access must be maximized at the highest possible price
John Wiley and Sons Ltd, Aug 2010, Pages: 355
Metabolism.
6.5 Efficacy and Safety.
6.6 Syntheses.
6.7 References.
Chapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor (Martin Pettersson).
7.1 Background.
7.2 Discovery and Development.
7
Business Monitor International, June 2009, Pages: 72
cancer treatment Tarceva (erlotinib) and Pfizer’s kidney cancer drug Sutent (sunitinib). Nevertheless, as a result of the implementation of tendering systems for medicines, as part of recent procurements
John Wiley and Sons Ltd, March 2008, Pages: 272
, the summary of its industrial development, the year put into practice, the biological target for the medicine, the human proteins related to the disease, the metabolism or action of the condition treated
Informa Healthcare, Jan 2006, Pages: 822
levels of the industry and recent developments.
Scrip Yearbook 2007 will help you to:
- Identify which significant mergers and acquisitions were completed
- Analyse the strategic and financial
